| scholarly article | Q13442814 |
| P2093 | author name string | Takashi Igarashi | |
| Toshiro Fujita | |||
| Yuji Yamazaki | |||
| Seiji Fukumoto | |||
| Itaru Urakawa | |||
| Takeyoshi Yamashita | |||
| Choni Rinat | |||
| Rachel Becker-Cohen | |||
| Sofia Feinstein | |||
| Yaacov Frishberg | |||
| Nobuaki Ito | |||
| Paulina Navon-Elkan | |||
| Kaori Araya | |||
| P2860 | cites work | Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent | Q24319643 |
| P433 | issue | 2 | |
| P921 | main subject | congenital disorder | Q55014976 |
| congenital disorder | Q727096 | ||
| glycosylation | Q898365 | ||
| P304 | page(s) | 235-242 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. | |
| P478 | volume | 22 |
| Q39074268 | A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice |
| Q35783146 | A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells |
| Q37216979 | A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features |
| Q28482201 | A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis |
| Q37210780 | Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression |
| Q92089727 | Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation |
| Q33911414 | An O-glycosyltransferase promotes cell adhesion during development by influencing secretion of an extracellular matrix integrin ligand |
| Q90378058 | Bone involvement and mineral metabolism in Williams' syndrome |
| Q34418714 | Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. |
| Q37641052 | Clinical relevance of FGF-23 in chronic kidney disease |
| Q35067500 | Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease |
| Q37417445 | Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis |
| Q35590824 | Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis |
| Q37367279 | Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia |
| Q37507342 | Disorders of phosphate homeostasis and tissue mineralisation |
| Q37092161 | Dosage effect of a Phex mutation in a murine model of X-linked hypophosphatemia |
| Q90209853 | Effects of erythropoietin on fibroblast growth factor 23 in mice and humans |
| Q36742425 | Enhanced mass spectrometric mapping of the human GalNAc-type O-glycoproteome with SimpleCells |
| Q84904076 | Evaluation of a new automated chemiluminescence immunoassay for FGF23 |
| Q27015054 | Exploring mechanisms of FGF signalling through the lens of structural biology |
| Q54960612 | FGF23 Actions on Target Tissues-With and Without Klotho. |
| Q64040255 | FGF23 and its role in X-linked hypophosphatemia-related morbidity |
| Q37584801 | FGF23 and syndromes of abnormal renal phosphate handling |
| Q38540953 | FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism. |
| Q37327002 | Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis |
| Q36413230 | Fibroblast growth factor 23: state of the field and future directions |
| Q55424941 | Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients. |
| Q27010789 | Fibrous dysplasia and fibroblast growth factor-23 regulation |
| Q38353574 | GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity |
| Q87423212 | Galnt3 deficiency disrupts acrosome formation and leads to oligoasthenoteratozoospermia |
| Q38785985 | Genetic Variants Associated with Circulating Parathyroid Hormone |
| Q34185739 | Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse |
| Q39118846 | Heritable and acquired disorders of phosphate metabolism: Etiologies involving FGF23 and current therapeutics |
| Q37781747 | Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease |
| Q38345898 | Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action |
| Q37401244 | Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis |
| Q37384718 | Latest findings in phosphate homeostasis |
| Q34273172 | Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature |
| Q39751663 | Loss of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis |
| Q33982618 | Mineral metabolism and aging: the fibroblast growth factor 23 enigma |
| Q36986492 | Mineralization/anti-mineralization networks in the skin and vascular connective tissues |
| Q26827280 | Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho) |
| Q92610642 | Molecular basis for fibroblast growth factor 23 O-glycosylation by GalNAc-T3 |
| Q36956055 | Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis |
| Q37475258 | Molecular pathology of the fibroblast growth factor family |
| Q33660188 | Newly discovered mutations in the GALNT3 gene causing autosomal recessive hyperostosis-hyperphosphatemia syndrome |
| Q35203230 | Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein |
| Q34249099 | Overexpression of Galnt3 in chondrocytes resulted in dwarfism due to the increase of mucin-type O-glycans and reduction of glycosaminoglycans |
| Q41865104 | Phosphate metabolism and vitamin D. |
| Q34690795 | Phosphate sensing |
| Q36757962 | Premature aging in klotho mutant mice: cause or consequence? |
| Q37130137 | Recent insights into the biological roles of mucin-type O-glycosylation |
| Q92889691 | Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF |
| Q36649088 | Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. |
| Q36988383 | Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases |
| Q38901793 | Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type |
| Q36843642 | Systemic Control of Bone Homeostasis by FGF23 Signaling |
| Q92959917 | The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia |
| Q36860289 | The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis |
| Q36832542 | Tumoral calcinosis: new insights for the rheumatologist into a familial crystal deposition disease |
| Q36832673 | Vitamin D and aging: old concepts and new insights |
Search more.